{"entity":{"id":"pbp1510","kind":"drug","name":"PBP1510","aka":[],"tldr":"PBP1510 is a monoclonal antibody from Prestige Biopharma Limited, in registered phase 2 trials for pancreatic ductal adenocarcinoma.","summary":"PBP1510 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Prestige Biopharma Limited, in pancreatic ductal adenocarcinoma. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of PBP1510","url":"https://clinicaltrials.gov/search?intr=PBP1510"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05141149"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"PBP1510","modality":"Monoclonal antibody","mechanism":"A monoclonal antibody, as described in the registry record.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/pbp1510/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"trial":[{"id":"nct05141149","kind":"trial","name":"First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer","route":"/trials/nct05141149/"}]}}